Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-09-19
2006-09-19
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S048000, C514S052000, C514S102000, C514S103000, C514S140000, C514S143000
Reexamination Certificate
active
07109181
ABSTRACT:
The present invention is directed to a method of altering the amount or composition of synovial fluids secreted from joints in a subject in need of such treatment. The method comprises administering to a subject a pharmaceutical composition comprising a P2Y purinergic receptor agonist in an amount effective to alter the amount or composition of synovial fluids. The P2Y purinergic receptor agonist is administered in an amount effective to stimulate secretion of synovial fluid, lubricin, hyaluronic acid, or surface-active phospholipids; to enhance joint lubrication; or to treat osteoarthritis. The pharmaceutical compositions useful in the present invention comprise a P2Y purinergic receptor agonist of Formula I and include, but are not limited to: uridine-, adenosine-, cytidine-5′-di- or triphosphates, dinucleoside polyphosphates, and analogs thereof. The invention is useful for treating conditions associated with reduced joint lubrication and joint stiffness, such as osteoarthritis.
REFERENCES:
patent: 5292498 (1994-03-01), Boucher, Jr.
patent: 5415873 (1995-05-01), Trepel et al.
patent: 5628984 (1997-05-01), Boucher, Jr.
patent: 5635160 (1997-06-01), Stutts, III et al.
patent: 5656256 (1997-08-01), Boucher et al.
patent: 5763447 (1998-06-01), Jacobus et al.
patent: 5789391 (1998-08-01), Jacobus et al.
patent: 5837861 (1998-11-01), Pendergast et al.
patent: 5900407 (1999-05-01), Yerxa et al.
patent: 5902567 (1999-05-01), Boucher, Jr.
patent: 5935555 (1999-08-01), Stutts, III et al.
patent: 5958897 (1999-09-01), Jacobus et al.
patent: 5968913 (1999-10-01), LaCroix et al.
patent: 5972904 (1999-10-01), Jacobus et al.
patent: 5981506 (1999-11-01), Jacobus et al.
patent: 5985849 (1999-11-01), Kindon et al.
patent: 6022527 (2000-02-01), Boucher, Jr. et al.
patent: 6133247 (2000-10-01), Boucher, Jr.
patent: 6133434 (2000-10-01), Buell et al.
patent: 6143279 (2000-11-01), Boucher, Jr. et al.
patent: 6323187 (2001-11-01), Yerxa et al.
patent: WO94/08593 (1994-04-01), None
patent: WO96/40059 (1996-12-01), None
patent: WO97/05195 (1997-02-01), None
patent: WO97/29756 (1997-08-01), None
patent: WO97/35591 (1997-10-01), None
patent: WO98/03177 (1998-01-01), None
patent: WO98/15835 (1998-04-01), None
patent: WO98/03182 (1998-05-01), None
patent: WO98/19685 (1998-05-01), None
patent: WO98/34593 (1998-08-01), None
patent: WO99/09998 (1999-03-01), None
patent: WO99/32085 (1999-09-01), None
patent: WO99/61012 (1999-12-01), None
patent: WO98/34942 (2000-01-01), None
patent: WO00/30629 (2000-06-01), None
patent: WO00/50024 (2000-08-01), None
International Search Report filed Nov. 5, 2002.
Benali et al., “Effect of Extracellular ATP and UTP on Fluid Transport by Human Nasal Epithelial Cells in Culture,”Am. J. Respir. Cell. Mol. Biol.10:363-368 (1994).
Bora et al., “Joint Physiology, Cartilage Metabolism, and the Etiology of Osteroarthritis,”Hand Clin.3:325-336 (1987).
Brown et al., “Evidence that UTP and ATP Regulate Phospholipase C through a Common Extracellular 5′-Nucleotide Receptor in Human Airway Epithelial Cells,”Mol. Pharmacol.40:648-655 (1991).
Delecrin et al., “Changes in Joint Fluid After Total Arthroplasty,”Clin. Orthop.307:240-249 (1994).
Drutz et al., “Uridine 5′ Triphosphate (UTP) Regulates Mucociliary Clearance via Purinergic Receptor Activation,”Drug Dev. Res.37(3):185 (1996).
Gobran et al., “P2uPurinoceptor Stimulation of Surfactant Secretion Doubled to Phosphatidylcholine Hydrolysis in Type II Cells,”Am. J. Physiol.267:L625-L633 (1994).
Green et al., “Purinergic Regulation of Bradykinin-induced Plasma Extravasation and Adjuvant-induced Arthritis in the Rat,”Proc. Natl. Acad. Sci.,88(10):4162-5 (1991).
Hills et al., “Deficiency of Lubricating Subfactant Lining the Articular Sufaces of Replaced Hips and Knees,”Br. J. Rheumatol.37:143-147 (1998).
Hills et al., “Boundary Lubrication in vivo,”Proc. Inst. Mech. Eng.214:83-94 (2000).
Hosoya et al., “Nucleotide Stimulation of CI Secretion in the Pigmented Rabbit Conjunctiva,”J. Pharmacol. Exp. Ther.291(1):53-59 (1999).
Jay et al., “Characterization of a Bovine Synovial Fluid Lubricating Factor III. The Interaction with Hyaluronic Acid,”Connect. Tissue Res.28:245-255 (1992).
Jay et al., “Comparison of the boundary-lubricating ability of bovine synovial fluid, lubricin, and Healon,”J. Biomed. Matl. Res.40:414-418 (1998).
Jay et al., “Lubricin Is a Product of Megakaryocyte Stimulating Factor Gene Expression by Human Synovial Fibroblasts,”J. Rheumatol.27:594-600 (2000).
Jumblatt et al., “Regulation of Ocular Mucin Secretion by P2Y2Nucleotide Receptors in Rabbit and Human Conjunctiva,”Exp. Eye Res.67:341-346 (1998).
Knowles et al., “Activation by Extracellular Nucleotides of Chloride Secretion in the Airway Epithelia of Patients with Cystic Fibrosis”New Engl. J. Med.325:533-538 (1991).
Lethem et al., “Nucleotide Regulation of Goblet Cells in Human Airway Epithelial Explants: Normal Exocytosis in Cystic Fibrosis,”Am. J. Respir. Cell. Mol. Biol.9:315-322 (1993).
Marshall et al., “Intra-articular hyaluronan therapy,”Curr. Opin. Rheumatol.12:468-474 (2000).
Mason et al., “Regulation of Transepithelial Ion Transport and Intracellular Calcium by Extracellular ATP in Human Normal and Cystic Fibrosis Airway Epithelium,”Br. J. Pharmacol.103:1649-1656 (1991).
Mundasad et al., “Ocular Safety on INS365 Ophthalmic Solution: A P2Y2Agonist in Healthy Subjects,”J. Ocul. Pharmacol. Ther.17(2):173-179 (2001).
Murakami et al., “P2Y2Receptor Stimulation Increases Tear Fluid Secretion in Rabbits,”Curr. Eye Res.21(4):782-787 (2000).
Murakami et al., “P2Y2Receptor Stimulation Increases Mucin-Like Glycoprotein Secretion from Rabbit Conjunctival Goblet Cells in vivo,”Invest. Ophthalmol. Vis. Sci.41(4):S457 (ARVO Abstract 2423 (2000).
Rabinowitz et al., “Lipid Composition of the Tissues of Human Knee Joints,”Clinical Orthopedics and Related Res.190:292-298 (1984).
Schwarz et al., “Synovial Surfactant: Lamellar Bodies in Type B Synoviocytes and Proteolipid in Synovial Fluid and the Articular Lining,”Br. J. Rheumatol.35:821-827 (1996).
Shiue et al., “Pharmacological Modulation of Fluid Secretion in the Pigmented Rabbit Conjunctiva,”Life Sci.66(7):PL105-111 (2000).
Yerxa et al., “P2Y2Receptor Agonists: Structure, Activity and Therapeutic Utility,”Drugs of the Future24(7):759-769 (1999).
Loredo & Benton, “ATP and UTP Activate Calcium-Mobilizing P2U-like Receptors and Act Synergistically with Interleukin-1 to Stimulate Prostaglandin E2Release from Human Rheumatoid Synovial Cells,”Arthritis&Rheumatism41:2 pp. 246-255 (1998).
Brown Edward G.
Cowlen Matthew S.
Jones Arthur C.
Yerxa Benjamin R.
Howrey LLP
Inspire Pharmaceuticals Inc.
Jiang Shaojia Anna
Krishnan Ganapathy
Kung Viola T.
LandOfFree
Joint lubrication with P2Y purinergic receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Joint lubrication with P2Y purinergic receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Joint lubrication with P2Y purinergic receptor agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3614520